Browse All Protocols and Pathways

All
  • All
  • Protocols and pathways
Using DMTs in MS- ABN 2024 guidance

Using DMT’s in MS: ABN 2024 guidance

By Aimee.Milne | March 19, 2025
2023 01 Summary of the NHSE commissioning criteria for MS DMTs (3) (1)

Summary of the NHSE commissioning criteria for MS DMTs (Blueteq criteria)

By Sian McKay | December 11, 2023

Screening Call Process Overview

By Transforming MS For All | August 7, 2023

Poster from ABN 2021 virtual MS clinics during a global pandemic the patients perspective Belfast

By Transforming MS For All | August 7, 2023

Poster from ABN 2021 translating logisitocal challenges into service improvements MS infusional services during COVID Belfast

By Transforming MS For All | August 7, 2023

Patient Review Proforma V9 (3)

By Transforming MS For All | August 7, 2023
1226018 Novartis_PlymouthRoadmap_V10.0_160223_FUSE (1) (6)

A look at the implementation of a multiple sclerosis screening initiative at University Hospitals Plymouth NHS Trust

By Transforming MS For All | August 7, 2023
Teriflunomide protocol - Cambridge - November 2021

Teriflunomide protocol Cambridge November 2021

By Transforming MS For All | August 7, 2023

Siponimod protocol Cambridge February 2022

By Transforming MS For All | August 7, 2023

Ponesimod protocol Cambridge August 2022

By Transforming MS For All | August 7, 2023